Morgan Stanley lowered the firm’s price target on Tenaya Therapeutics (TNYA) to $2 from $5 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech’s outperformance in 2026 as commercial names transition from “capital consumers to producers” and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNYA:
- Tenaya Therapeutics announces orderly board leadership transition
- Tenaya Therapeutics price target lowered to $4 from $6 at Canaccord
- Promising Initial Data and Safety Profile Justify Buy Rating for Tenaya Therapeutics’ TN-401
- Tenaya Therapeutics Announces Public Offering Pricing
- Promising Clinical Developments and FDA Approval Boost Tenaya Therapeutics’ Buy Rating